dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ferrer Roca, Ricard |
dc.contributor.author | Fariñas, María Carmen |
dc.contributor.author | Salavert, Miguel |
dc.contributor.author | Bou, German |
dc.contributor.author | Díaz-Regañón, Jazmín |
dc.contributor.author | Maseda, Emilio |
dc.date.accessioned | 2022-03-14T13:07:34Z |
dc.date.available | 2022-03-14T13:07:34Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Ferrer R, Fariñas MC, Maseda E, Salavert M, Bou G, Díaz-Regañón J, et al. Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain. Rev Española Quimioter. 2021 Dec;34(6):639–50. |
dc.identifier.issn | 0214-3429 |
dc.identifier.uri | https://hdl.handle.net/11351/7163 |
dc.description | Carbapenemasa; Infeccions gramnegatives; Infeccions associades a l'assistència sanitària |
dc.description.sponsorship | Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. |
dc.language.iso | eng |
dc.publisher | Sociedad Española de Quimioterapia |
dc.relation.ispartofseries | Revista Española de Quimioterapia;34(6) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Malalties bacterianes gramnegatives - Tractament |
dc.subject | Respiració artificial |
dc.subject | Infeccions nosocomials |
dc.subject.mesh | Gram-Negative Bacterial Infections |
dc.subject.mesh | Cross Infection |
dc.subject.mesh | Ventilators, Mechanical |
dc.subject.mesh | /adverse effects |
dc.title | Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.37201/req/096.2021 |
dc.subject.decs | infecciones por bacterias gramnegativas |
dc.subject.decs | infección hospitalaria |
dc.subject.decs | ventiladores mecánicos |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | http://www.doi.org/10.37201/req/096.2021 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ferrer R] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Fariñas MC] Hospital Marqués de Valdecilla, Santander, Spain. [Maseda E] Hospital Universitario La Paz, Madrid, Spain. [Salavert M] Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Bou G] Hospital Universitario A Coruña, La Coruña, Spain. [Díaz-Regañón J] MSD, Madrid, Spain |
dc.identifier.pmid | 34806858 |
dc.identifier.wos | 000747675600009 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |